Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011.
The 2009 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension (PH) have been adopted for Germany. While the guidelines contain detailed recommendations regarding pulmonary arterial hypertension (PAH), they contain only a relatively short paragraph on other, much more frequent forms of PH including PH owing to left heart disease. The guidelines point out that the drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors) have not been sufficiently investigated in other forms of PH. However, despite the lack of respective efficacy data an uncritical use of targeted PAH drugs in patients with PH associated with left heart disease is currently observed at an increasing rate. This development is a matter of concern. On the other hand, PH is a frequent problem that is highly relevant for morbidity and mortality in patients with left heart disease. It that sense, the practical implementation of the European Guidelines in Germany requires the consideration of several specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2010, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to PH due to left heart disease. This commentary describes in detail the results and recommendations of the working group which were last updated in October 2011.
Clinic III for Internal Medicine, Heart Center at University of Cologne, Cologne, Germany. stephan.rosenkranz@uk-koeln.de
Stephan
S
Rosenkranz
Diana
D
Bonderman
Michael
M
Buerke
Ralf
R
Felgendreher
Henrik
H
ten Freyhaus
Ekkehard
E
Grünig
Fokko
F
de Haan
Christoph
C
Hammerstingl
Alexander
A
Harreuter
Wolfgang
W
Hohenforst-Schmidt
Ingrid
I
Kindermann
Michael
M
Kindermann
Franz X
FX
Kleber
Matthias
M
Kuckeland
Wolfgang M
WM
Kuebler
Dirk
D
Mertens
Veselin
V
Mitrovic
Christian
C
Opitz
Alexander
A
Schmeisser
Uwe
U
Schulz
Rudolf
R
Speich
Wolfgang
W
Zeh
Joachim
J
Weil
D005858:Germany; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011453:Prostaglandins / Q000627:therapeutic use*
D058986:Phosphodiesterase 5 Inhibitors; D011453:Prostaglandins